3-point major cardiovascular event outcome for patients with T2D treated with dipeptidyl peptidase-4 inhibitor or glucagon-like peptide-1 receptor agonist in addition to metformin monotherapy
Background: The worldwide incidence of sort 2 diabetes (T2D) continues to extend yearly, and individuals with T2D usually require common modifications… Continue Reading